Trial Profile
Phase I trial of vemurafenib and low-dose decitabine in patients with malignant melanoma
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 15 Jul 2015
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 15 Jul 2015 New trial record
- 02 Jun 2015 Due to the response rate in patients receiving vemurafenib + decitabine in a phase I/II trial (see trial profile 700233849), this phase I trial is planned to investigate the effect of decitabine given at a low dose for a longer duration to ensure maximal depletion of DNA methyltransferase, according to an ASCO abstract.